New scientific information from Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:MDNA) is strengthening confidence in its lead most cancers remedy, positioning the corporate as a notable participant within the subsequent wave of immuno-oncology therapies.
On April 28, the corporate acquired a Speculative Purchase score and a C$3.75 12-month worth goal from Analysis Capital analyst Andre Uddin following the discharge of recent constructive interim information from its MDNA11 scientific trial.
Medicenna offered up to date Part 1/2 outcomes for MDNA11 on the American Affiliation for Most cancers Analysis (AACR) Annual Assembly on April 27. The corporate stated the mix of MDNA11 and Keytruda achieved a notable goal response fee (ORR) of 36% throughout all tumour varieties, up from 22% reported in December 2024, whereas sustaining a beneficial security profile with greater than 90% of treatment-related hostile occasions being gentle or average.
“We’re inspired by the anti-tumour exercise and security of MDNA11 in each the monotherapy and mixture setting, together with the three latest responders, notably in sufferers who’ve proven resistance to checkpoint inhibitors or with tumour varieties with traditionally low responses to immunotherapies and addressing a vastly underserved most cancers inhabitants,” Medicenna president and CEO Fahar Service provider stated in a press launch discussing the outcomes launched on the AACR agm. “Right now’s efficacy and immunodynamic information have offered the muse to begin the dose enlargement portion for MDNA11 together with KEYTRUDA.
“Within the monotherapy setting, we proceed to see deep and sturdy single-agent exercise of MDNA11 with two sufferers remaining in full remission and off remedy. Collectively, these information reinforce the best-in-class potential for MDNA11 as a potent and protected immunotherapy that’s poised to remodel the prevailing therapy paradigm for sufferers with difficult-to-treat tumours.
“We sit up for sharing extra scientific information from the ABILITY-1 examine at future medical conferences this yr.”
Uddin stated the info strengthens the case for MDNA11 as a number one next-generation IL-2 remedy in stable tumours.
“MDNA11’s security profile, coupled with its sturdy interim efficacy, differentiates itself from different IL-2 drug candidates that generated weak efficacy information and poor security profiles,” Uddin wrote.
Uddin stated that Medicenna gained’t generate any income in fiscal 2025 or 2026, as the corporate is concentrated on scientific improvement and doesn’t anticipate materials product income but.
The analyst added that assuming MDNA11 continues to ship sturdy information, a licensing deal might occur as early as 2027, probably reworking the corporate’s valuation outlook.
“We stay bullish on MDNA’s elegant science and count on additional information all through calendar 2025,” Uddin stated. “Assuming that MDNA11 continues to generate compelling scientific information, we’d anticipate a licensing deal by early 2027.”
-30-
